StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. (Nasdaq:RPRX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/RPRX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. There is no currently-approved effective long-term drug treatment for uterine fibroids or endometriosis. In the United States alone, approximately 300,000 women per year undergo a hysterectomy as a result of severe uterine fibroids. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.

Message Board Search for RPRX: http://www.boardcentral.com/boards/RPRX

In the report, the analyst notes:

"Net loss for the three-month period ended December 31, 2009, was ($1.3) million or ($0.06) per share as compared to a net loss of ($5.9) million or ($0.39) per share for the same period in 2008. Net loss for the twelve-month period ended December 31, 2009 was ($27.2) million or ($1.57) per share as compared to ($25.2) million or ($1.88) per share for the same period in 2008. 

"RPRX recently announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex^® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity. Previously, on August 3, 2009, RPRX unilaterally suspended its then-ongoing Proellex® studies."